Option chain shows key data for Leef Brands's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Leef Brands.

Leef Brands (OTC:LEEED) Stock, Option Chain

Leef Brands Inc is a manufacturer of cannabis-branded products manufacturer based in California. It offers products under brand names like Real Deal Resin, Ganja Gold, Heady, and Leef. Geographically, it derives a majority of its revenue from the United States. It has one operation of the Company located in Canada and the United States. The Company has one reportable business segment in the cannabis sector. It generates the majority of its revenue from the USA.

Leef Brands Inc

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASMB

BDRX

BLRX

CATX

CDTX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) stock increased by 94.1% to $6.21 during Thursday's pre-market session. The company's market cap stands at $85.4 million. </li>
<li>SKK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares rose 31.57% to $6.0. The company's market cap stands at $93.7 million. </li>
<li>Palladyne AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) shares increased by 18.55% to $2.3. The company's market cap stands at $69.2 million. </li>
<li>CRA Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRAI#NASDAQ">CRAI</a>) stock increased by 12.59% to $216.88. The market value of their outstanding shares is at $1.4 billion. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock increased by 10.0% to $4.4. The company's market cap stands at $92.6 million. </li>
<li>Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) stock moved upwards by 9.68% to $15.41. The company's market cap stands at $356.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) stock fell 28.9% to $27.57 during Thursday's pre-market session. The company's market cap stands at $42.1 million. </li>
<li>noco-noco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares decreased by 14.98% to $0.14. The market value of their outstanding shares is at $26.6 million. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) stock decreased by 12.84% to $0.95. The company's market cap stands at $6.0 million. </li>
<li>Caravelle Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock declined by 10.45% to $1.2. The market value of their outstanding shares is at $66.9 million. </li>
<li>EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) shares declined by 9.23% to $13.87. The market value of their outstanding shares is at $881.5 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) stock fell 8.76% to $76.78. The company's market cap stands at $2.7 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGFY

ATKR

CRAI

HTCO

HUHU

KITT

NCNC

PDYN

SPAI

TITN

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) stock rose 24.5% to $160.8 during Thursday's pre-market session. The market value of their outstanding shares is at $53.9 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Akoustis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares moved upwards by 22.04% to $0.11. The company's market cap stands at $16.4 million. </li>
<li>Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) shares rose 21.62% to $9.0. The company's market cap stands at $53.8 million. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) stock rose 21.05% to $1.84. The market value of their outstanding shares is at $32.5 million. </li>
<li>Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) shares rose 18.08% to $3.33. The company's market cap stands at $139.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock moved upwards by 15.48% to $4.25. The market value of their outstanding shares is at $502.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock decreased by 15.2% to $0.42 during Thursday's pre-market session. The company's market cap stands at $12.4 million. </li>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock decreased by 11.29% to $0.21. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares declined by 8.73% to $3.03. The market value of their outstanding shares is at $64.4 million. </li>
<li>CSP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSPI#NASDAQ">CSPI</a>) stock declined by 7.82% to $12.51. The market value of their outstanding shares is at $122.1 million. </li>
<li>Backblaze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLZE#NASDAQ">BLZE</a>) stock decreased by 7.71% to $5.75. The market value of their outstanding shares is at $255.3 million. </li>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) stock decreased by 5.36% to $0.16. The market value of their outstanding shares is at $8.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKTS

BLZE

CETX

CRNC

CSPI

LAES

QUBT

SNOW

ZENA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

News

REPL

Replimune Receives Breakthrough Therapy Designation For RP1, Submits RP1 Biologics License Application To FDA Under Accelerated Approval Pathway

WIIM

INTU

Intuit shares are trading lower after the company issued Q2 adjusted EPS and revenue guidance below analyst estimates.

Forward-looking Guidance
Intuit reiterated guidance for the full fiscal year 2025. The company expects:
<ul>
<li>Revenue of $18.160 billion to $18.347 billion, growth of approximately 12 to 13 percent.</li>
<li>GAAP operating income of $4.649 billion to $4.724 billion, growth of approximately 28 to 30 percent.</li>
<li>Non-GAAP operating income of $7.241 billion to $7.316 billion, growth of approximately 13 to 14 percent.</li>
<li>GAAP diluted earnings per share of $12.34 to $12.54, growth of approximately 18 to 20 percent.</li>
<li>Non-GAAP diluted earnings per share of $19.16 to $19.36, growth of approximately 13 to 14 percent.</li>
</ul>
The company also reiterated full fiscal year 2025 segment revenue guidance:
<ul>
<li>Global Business Solutions Group: growth of 16 to 17 percent. This includes Online Ecosystem revenue growth of approximately 20 percent, and Desktop Ecosystem revenue growth in the low single digits.</li>
<li>Consumer Group: growth of 7 to 8 percent.</li>
<li>ProTax Group: growth of 3 to 4 percent.</li>
<li>Credit Karma: growth of 5 to 8 percent.</li>
</ul>

Guidance

Intuit Sees FY25 EPS $19.16-$19.36 Vs $19.33 Est.; Revenue $18.16B-$18.347B Vs $18.26B Est.

AAPL

Apple Aims To Launch Siri Revamp In 2026 With More In-House AI

NTAP

NetApp shares are trading higher following better-than-expected Q2 financial results.

Intuit announced guidance for the second quarter of fiscal year 2025, which ends January 31. The company expects:
<ul>
<li>Revenue of $3.812 billion to $3.845 billion, growth of approximately 13 to 14 percent. The company expects a single digit decline in Consumer Group revenue due to some promotional changes in retail channels largely related to its desktop offering. This only impacts revenue timing and does not impact overall unit or revenue expectations for fiscal year 2025. The company expects Global Business Solutions Group Desktop Ecosystem revenue to return to growth in the second quarter.</li>
<li>GAAP diluted earnings per share of $0.84 to $0.90.</li>
<li>Non-GAAP diluted earnings per share of $2.55 to $2.61.</li>
</ul>

Intuit Sees Q2 Adj. EPS $2.55-$2.61 Vs $3.25 Est.; Revenue $3.812B-$3.845B Vs $3.88B Est.

<a href="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf</a>

MSTR

MicroStrategy Completes $3B Offering Of 0% Convertible Senior Notes Due 2029, Including $400M Option Exercised By Initial Purchasers

Abacus intends to use net proceeds of the primary portion of the offering for its operations, including the purchase of life settlement policies, to support its overall business strategy, for working capital purposes, and for general corporate purposes, which may include funding previously announced and future acquisitions and repayment and refinancing of its indebtedness. Abacus will receive no proceeds from the secondary portion of the offering.

Offerings

Abacus Life Commences Public Offering Of 12.50M Shares Of Its Common Stock, Including 10M Shares By  Company And 2.50M To Be Sold By Certain Stockholders

NetApp Sees Q3 FY25 Revenue $1.61B-$1.76B, GAAP EPS $1.41-$1.51, Non-GAAP EPS $1.85-$1.95; Sees FY25 Revenue $6.54B-$6.74B, GAAP EPS $5.48-$5.68, Non-GAAP EPS $7.20-$7.40

Highly anticipated movies "Wicked" and "Gladiator II" are being released on the same day and come shortly ahead of "Moana 2," setting up what could be a record-breaking Thanksgiving weekend for the <a href="https://www.benzinga.com/news/earnings/24/11/41790068/amc-ceo-is-confident-and-optimistic-about-cinema-chains-future-as-q3-earnings-show-revenue-beat-rec">movie theater industry</a>.
What Happened: "Wicked" and "Gladiator II" open in domestic movie theaters on Nov. 22, in a move that some compared to the release of "Barbie" and "Oppenheimer" on the<a href="https://www.benzinga.com/general/entertainment/24/07/39621420/wicked-gladiator-2-same-day-release-has-industry-vying-for-another-box-office-power-duo-bar"> same day last year.</a>
While "Glicked" or whatever acronym you want to use for seeing both movies the same day didn't catch on as big as last year's "Barbenheimer" did previously, expectations remain high for both movies.
"Wicked," which comes from Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) unit Universal Pictures, is expected to post a domestic opening weekend total in the range of $125 million to $150 million, as <a href="https://deadline.com/2024/11/wicked-gladiator-box-office-preview-1236181463/">reported </a>by Deadline.
"Gladiator II," which comes from Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), is expected to have a domestic opening weekend of more than $60 million.
Deadline reports strong initial audience scores for "Wicked" from those who saw early screenings of the film and pre-sales that are "through the roof."
As an R-rated movie, a total of $60 million or more could help "Gladiator II" become the highest-grossing R-rated film in November.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41987956/airbnb-says-are-you-not-entertained-new-roman-colosseum-experience-coincides-with-gladiator-sequel">Airbnb Says &#8216;Are You Not Entertained?&#8217; New Roman Colosseum Experience Coincides With Gladiator Sequel</a>
Why It's Important: The strong expected opens for "Wicked" and "Gladiator II" could be good news for AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) and Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) and other movie theater operators in the U.S.
Along with those two movies, movie theaters could also benefit from the release of "Moana 2" from Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), which comes next Wednesday, ahead of the Thanksgiving holiday.
The three movies could help the domestic box office pass $300 million and hit all-time records for the holiday five-day weekend, <a href="https://www.hollywoodreporter.com/movies/movie-news/box-office-record-thanksgiving-feast-1236067367/">according </a>to The Hollywood Reporter.
With three strong movies all released shortly before Thanksgiving, estimates predict a strong domestic box office next week, which could be another bright spot in the post-COVID-19 recovery for movie theaters and movie companies.
A total of over $300 million, with most coming from the three films, could come close to the record. Here's a look at the current top-grossing five-day domestic Thanksgiving weekends and the highest-grossing film during the time period:
<ul>
<li>2018: $315.6 million, "Ralph Breaks the Internet" ($84.8 million)</li>
<li>2013: $294.2 million, "The Hunger Games: Catching Fire" ($109.9 million)</li>
<li>2017: $270.5 million, "Coco" ($72.9 million)</li>
<li>2019: $263.4 million, "Frozen II" ($125.0 million)</li>
<li>2016: $260.0 million, "Moana" ($125.0 million)</li>
</ul>
The report said current tracking predicts "Moana 2" will gross between $125 million and $150 million for the five-day holiday weekend domestically, which would break records for the time period.
The early Wednesday opening could contribute to the strong expectations for "Moana 2" as not all blockbusters haven't done this same holiday release window previously, the report added.
While the strong opening expectations for the three films could help the movie companies behind them, the big winners will likely be the movie theaters as they could see many customers coming in more than once during a period that might have only drawn one visit in past years due to this year's strong lineup.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/07/39718738/elon-musk-predicts-gladiator-sequel-will-be-painfully-bad-embarrassingly-so-films-star-says">Elon Musk Predicts Gladiator Sequel Will Be &#8216;Painfully Bad. Embarrassingly So&#8217;: Film&#8217;s Star Says Movie Takes &#8216;New Direction&#8217;</a></li>
</ul>
Photo: Movie posters via IMDb

Entertainment

Trading Ideas

CMCSA

PARA

PARAA

'Wicked,' 'Gladiator II,' 'Moana 2' Could Break Thanksgiving Weekend Box Office: Stocks To Watch

Management

FLUX

Flux Power Chairman & CEO Ron Dutt To Retire

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.40 by 5.71 percent. This is a 11.28 percent increase over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $5.07 billion which missed the analyst consensus estimate of $5.15 billion by 1.45 percent. This is a 2.97 percent increase over sales of $4.92 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

ROST

Ross Stores Q3 EPS $1.48 Beats $1.40 Estimate, Sales $5.07B Miss $5.15B Estimate

NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.78 by 5.06 percent. The company reported quarterly sales of $1.658 billion which beat the analyst consensus estimate of $1.645 billion by 0.79 percent. This is a 6.15 percent increase over sales of $1.562 billion the same period last year.

NetApp Q2 2025 Adj. EPS $1.87 Beats $1.78 Estimate, Sales $1.658B Beat $1.645B Estimate

Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) reported quarterly earnings of $2.50 per share which beat the analyst consensus estimate of $2.35 by 6.38 percent. This is a 1.21 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $3.28 billion which beat the analyst consensus estimate of $3.14 billion by 4.59 percent. This is a 10.24 percent increase over sales of $2.98 billion the same period last year.

Intuit Q1 2025 Adj EPS $2.50 Beats $2.35 Estimate, Sales $3.28B Beat $3.14B Estimate

Ark Invest CEO Cathie Wood has laid out several price targets for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) including a bull case of $3.8 million if more companies add the cryptocurrency to their balance sheet. Benzinga readers see this price target as not likely to be reached by<a href="https://www.benzinga.com/general/education/24/11/42017619/heres-how-much-100-in-bitcoin-could-be-worth-in-2030-if-cathie-woods-price-target-is-reached"> Wood's projection of 2030.</a>
What Happened: Wood has shared several price targets for Bitcoin over the years, which might seem more realistic given that the leading cryptocurrency <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone" target="_blank" rel="noopener">has hit</a><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone"> multiple all-time highs </a>since the 2024 presidential election.
Earlier this year, Wood laid out <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/02/30660447/cathie-woods-ark-sees-bitcoin-joining-trillion-dollar-club-by-2030-here-are-its-bea" target="_blank" rel="noreferrer noopener">her price targets </a>for Bitcoin based on a bear case, base case and bull case for the year 2030. Wood also added a new bull case that includes the highest price Bitcoin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37902973/cathie-wood-says-bitcoin-could-skyrocket-to-3-8m-by-2030-thanks-to-institutional-gr" target="_blank" rel="noreferrer noopener">could potentially reach by 2030</a> if companies allocated 5% to Bitcoin.
<ul>
<li>The price targets are:</li>
<li>Bear Case: $258,500</li>
<li>Base Case: $682,000</li>
<li>Bull Case: $1,480,000</li>
<li>Bullish Case: $3,800,000</li>
</ul>
Benzinga recently asked readers if they thought Wood's highest price target could be reached by the year 2030.
"Will Cathie Wood's Bitcoin price prediction of $3.8 million by 2030 come true?" Benzinga asked.
The results were:
<ul>
<li>No, Bitcoin will never reach $3.8 million: 34%</li>
<li>No, Bitcoin won't reach $3.8 million by 2030: 25%</li>
<li>Bitcoin could reach $3.8 million, but not by 2030: 24%</li>
<li>Yes, Bitcoin will reach $3.8 million by 2030: 17%</li>
</ul>
The poll found that only 17% of readers said that Bitcoin is likely to hit $3.8 million by 2030. The highest percentage of readers said Bitcoin will never reach the $3.4 million price target. The remaining readers see Bitcoin potentially hitting $3.8 million, but it will come after 2030.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don't?</a>
Why It's Important: Part of Wood's thesis hinges on corporations adding Bitcoin to their balance sheet.
MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the most famous example of this. The software company continues to invest its profits in Bitcoin and <a href="https://www.benzinga.com/24/11/42118133/short-seller-andrew-left-targets-microstrategy-stock-as-hedge-against-bullish-bitcoin-bet-completely-detached-from-btc-fundamentals" target="_blank" rel="noopener">borrow to continue investing</a> in Bitcoin.
Other companies, such as Tesla Inc. and Block Inc., added Bitcoin to their balance sheets, but in lower quantities than MicroStrategy.
MicroStrategy Chairman Michael Saylor recently said <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">he will be presenting</a> to the Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Board of Directors on why the tech giant should add Bitcoin to their balance sheet. The item was proposed to the company and could mark one of the largest companies to buy Bitcoin if the deal goes through.
Saylor also said he would advise Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>), whose CEO is considering buying Bitcoin.
There is also the potential that the new White House administration will advance<a href="https://www.benzinga.com/news/events/24/11/42071064/exclusive-anthony-pompliano-calls-for-us-to-buy-250b-bitcoin-on-day-1-of-trump-administration-protect-our-future-its-such-a-no-brainer"> calls to buy Bitcoin</a> for a strategic reserve.
With a fixed maximum supply of 21 million Bitcoin, the demand from corporations and country governments to add BTC to reserves and balance sheets would likely spike the price, which was the key thesis of Wood's price target.
Wood recently reiterated her price targets in a CNBC <a href="https://x.com/BitcoinMagazine/status/1857483221857865879" target="_blank" rel="noreferrer noopener">interview</a><a href="https://x.com/BitcoinMagazine/status/1857483221857865879" target="_blank" rel="noopener">,</a> highlighting Ark Invest&#8217;s early investment in Bitcoin.
&#8220;We were the first public asset manager to gain exposure to Bitcoin in 2015 at $250,&#8221; Wood said.
Wood said that even with Bitcoin trading at around $90,000, the company believes there is a long way to go.
The fund manager said that getting regulatory relief with a new administration is one of the most important things for Bitcoin. Wood also sees Bitcoin being viewed as a new asset class, leading to more institutions and asset allocators wanting to invest in the top cryptocurrency.
Wood's Ark Invest&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36605838/ark-invest-ceo-cathie-wood-projects-a-single-bitcoin-could-be-worth-1-5m-by-2020-probabili" target="_blank" rel="noreferrer noopener">was also one of several companies&nbsp;</a>to have a Bitcoin ETF approved by the SEC with its&nbsp;Ark 21 Shares Bitcoin ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>).
BTC Price Action: Bitcoin trades at $98,617.47 at the time of writing and is up 123% year-to-date in 2024. A <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951961/bitcoin-to-100k-benzinga-readers-predict-if-btc-can-hit-new-milestone-before-end-of-2024">recent Benzinga poll </a>found that 73% of readers believe Bitcoin will reach $100,000 by the end of 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a></li>
</ul>
The study was conducted by Benzinga from Nov. 14 through Nov. 15, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 156 adults.
Image created using a photo from Ark Invest and Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

MSFT

Cathie Wood's $3.8 Million Bitcoin Vision Met With Doubt: 83% Say Not By 2030

On Wednesday, justice reform advocates, formerly incarcerated people and their families as well as the Last Prisoner Project joined Reps. Ayanna Pressley, James E. Clyburn, Mary Gay Scanlon, Ilhan Omar and other congressional leaders to announce their joint letter urging President Biden to grant clemency to non-violent federal cannabis prisoners before his term ends. "Now is the time to use your clemency authority to rectify unjust and unnecessary criminal laws passed by Congress and draconian sentences given by judges," reads the <a href="https://s3.documentcloud.org/documents/25354946/2024-11-20-letter-to-president-biden-on-clemency.pdf">letter</a>. "We urge you to use your executive clemency power to reunite families, address longstanding injustices in our legal system, and set our nation on the path toward ending mass incarceration."
Reps. Pressley, Clyburn, and Gay Scanlon led the letter signed by a total of 67 Democratic members of Congress.
"You have the support of millions of people across the country who have felt the harms of mass incarceration: young children longing to hug their grandparents, people who have taken responsibility for their mistakes, and those who simply were never given a fair chance. These are the people seeking help that only you can provide through the use of your presidential clemency power," the letter concludes.
Congresswoman Ilhan Omar commented, &#8220;While cannabis is now legal in Minnesota and many states across America, thousands remain behind bars in federal prisons for the same substance – a reminder of the work still ahead. President Biden still has time to build on his initial pardons and take decisive action. He can extend clemency to every person still serving time for federal cannabis offenses, many of whom have already spent decades behind bars. In Minnesota, we&#8217;ve shown that cannabis legalization and expungement can move hand in hand. Now it&#8217;s time for federal action to match this progress.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Rep. Ayanna Pressley, Colleagues, Advocates Urge Biden to Use Clemency Power Before Leaving Office" width="500" height="281" src="https://www.youtube.com/embed/tTw2dJlUvfI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Recent Efforts</h2>
This action aligns with Last Prisoner Project's <a href="https://www.benzinga.com/markets/cannabis/24/09/40805469/biden-faces-pressure-to-release-thousands-imprisoned-for-federal-cannabis-convictions">#Countdown4Clemency campaign</a>, which is focusing public pressure on Biden to use his clemency power before the end of his presidency to free those still incarcerated in federal prison for cannabis crimes so they can be reunited with their families. The nonprofit cannabis justice reform organization recently urged the president to <a href="https://www.benzinga.com/markets/cannabis/24/11/42087262/president-biden-people-are-still-in-jail-for-marijuana-despite-your-promise-cannabis-clemency-advocates-call-for-change">#PardonPeopleNotPoultry</a> and end the incarceration of thousands for cannabis offenses now legal in many states.
LPP stressed that Biden has <a href="https://www.benzinga.com/markets/cannabis/24/09/40885403/biden-has-not-freed-anyone-in-prison-for-cannabis-crime-last-prisoner-project-urges-president-to" target="_blank" rel="noreferrer noopener">not released a single person</a> still incarcerated for cannabis through commutation. While his <a href="https://www.benzinga.com/markets/cannabis/24/11/42087262/Biden%20Pardons%20Thousands%20Convicted%20Of%20Cannabis%20Possession,%20Calls%20On%20Governors%20To%20Do%20The%20Same" target="_blank" rel="noreferrer noopener">categorical pardons</a> provided record relief to thousands of people with cannabis possession convictions, this move alone does not address the estimated 3,000 people still serving time in federal prisons for cannabis offenses.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39319868/meet-the-man-who-did-prison-time-for-non-violent-cannabis-offense-and-now-advocates-for-others-i">Meet The Man Who Did Prison Time For Non-Violent Cannabis Offense And Now Advocates For Others In The Same Situation</a>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519-1024x683.jpg" alt="" class="wp-image-658581" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061829/LPP-6519.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Latino Fathers In Jail</h2>
 Mitzi Wall, whose son Jonathan Wall is incarcerated on an eight-year federal cannabis charge, said, "Earlier this year I attended the historic pardon action where Maryland Gov. Wes Moore used the pen to right history to grant clemency <a href="https://www.benzinga.com/markets/cannabis/24/06/39357557/maryland-gov-to-pardon-175k-low-level-cannabis-convictions-in-the-nations-most-far-reaching-and-">to more than 175,000 cannabis possession and paraphernalia charge</a>s. Yet other Marylanders like my son, Jonathan Wall, who are incarcerated on federal cannabis charges, can only get that type of clemency relief by the president taking the pen."
Jason Ortiz, director of strategic initiatives at Last Prisoner Project, said "There are a heartbreaking number of Latino fathers incarcerated for life or near-life sentences for activity now happening legally across our nation. People like <a href="Meet The Man Serving A 40-Year Sentence For Non-Violent Cannabis Charges, Awaiting Pardon From Biden">Edwin Rubis</a> who is a father of three and has served 27 years of a 40-year sentence. President Biden has the power to reunite our families but the clock is running out."
Among those still behind bars is Ricardo Ashmeade, who is serving a 22-year sentence due to the three-strikes law championed by then-Senator Biden. His daughter, Richeda Ashmeade, has been separated from her father for 16 years. In addition to Ricardo, individuals like Rafael Hernandez-Carrillo, who is serving a life sentence for a cannabis-related offense, and David Lopez, who has faced years behind bars for court errors on his cannabis charges, exemplify the urgent need for clemency.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40885403/biden-has-not-freed-anyone-in-prison-for-cannabis-crime-last-prisoner-project-urges-president-to">Biden &#8216;Has Not Freed Anyone In Prison For Cannabis Crime&#8217;: Last Prisoner Project Urges President To Deliver On Promise</a></li>
</ul>
Photos via <a href="https://www.lastprisonerproject.org/last-prisoner-project-joins-25--congressmembers-in-joint-letter-urging-president-biden-to-invoke-clemency-powers">Last Prisoner Project</a>

Cannabis

67 Lawmakers Urge Biden To Grant Clemency To People Still In Jail For Cannabis Offenses

Innocan Pharma Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/INNPF#OTC">INNPF</a>), an Israel-based <a href="http://benzinga.com/cannabis">cannabinoids-focused</a> pharmaceutical company, reported a 174% year-over-year revenue growth, reaching $24 million for the first nine months of 2024. Quarterly revenues rose 111% YoY to $8.6 million, driven by robust sales from its subsidiary, BI Sky Global Ltd.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue was $8.6 million for the third quarter, up 111% year-over-year, and $24 million for the nine-month period, up 174% year-over-year.</li>
<li>Net income was $0.3 million, an increase of $2.1 million compared to a net loss of $1.8 million in Q3 2023.</li>
<li>Adjusted EBITDA was not stated in the press release.</li>
<li>Gross profit was $7.8 million for the third quarter, up 112% year-over-year.</li>
</ul>
Gross profit surged 183% YoY for the nine-month period, totaling $21.8 million, while Q3 gross profit grew 112% to $7.8 million. Operating profit turned positive, reaching $0.4 million, reversing a $1.2 million loss in Q3 2023.&nbsp;
Net profit also improved significantly, increasing by $2.1 million to $0.3 million for the quarter.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Management Commentary</h3>
Iris Bincovich, Innocan's CEO, attributed the strong performance to the company's dual focus on pharmaceutical innovation and wellness. She highlighted the company's progress in developing LPT-CBD, a proprietary non-opioid chronic pain management solution targeting both human and animal care. "Innocan is bringing strong value for shareholders," Bincovich <a href="https://www.newswire.ca/news-releases/innocan-pharma-reports-third-quarter-2024-financial-results-849241974.html">said</a>, emphasizing the company's commitment to addressing chronic pain.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42049450/can-trumps-return-save-the-cannabis-sector-debt-mounts-as-giants-face-post-election-reckoning">Can Trump&#8217;s Return Save The Cannabis Sector? Debt Mounts As Giants Face Post-Election Reckoning</a>
Roni Kamhi, of BI Sky Global and COO of Innocan Pharma, highlighted the company&#8217;s consistent growth. &#8220;We are pleased to report nine consecutive quarters of continuous revenue growth,&#8221; he stated. He credited new product launches and enhanced brand awareness for the success.
Innocan's financial gains underscore its strategic focus on innovation and market expansion, positioning the company as a rising player in the pharmaceutical sector. The company's results signal ongoing growth potential amid increasing demand for non-opioid pain management solutions.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42039385/enveric-biosciences-trims-losses-eyes-key-drug-approval-for-difficult-to-treat-mental-health-disorders">Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders</a></li>
</ul>

Comments

Leef Brands

Leef Brands (LEEED) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga